Cargando…
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both o...
Autores principales: | Kivelevitch, Dario, Mansouri, Bobbak, Menter, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000175/ https://www.ncbi.nlm.nih.gov/pubmed/24790410 http://dx.doi.org/10.2147/BTT.S41481 |
Ejemplares similares
-
Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes, Katie E, et al.
Publicado: (2016) -
Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019) -
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015) -
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018) -
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)